OneMedNet Converts Evaluations to Subscriptions, Bolsters Recurring Revenue
Event summary
- OneMedNet is actively converting customer evaluations of its RWD platform, powered by Palantir Foundry, into commercial subscriptions.
- The company demonstrated its platform’s capabilities at tradeshows in November 2025, showcasing live feeds, subscription access, and AI-driven search.
- OneMedNet’s iRWD network now encompasses over 2,130 healthcare sites.
- Early subscription contracts include multi-year deals representing millions in incremental recurring revenue.
The big picture
OneMedNet's commercial launch represents a significant step in the burgeoning real-world data market, which is increasingly vital for drug development, clinical trial optimization, and personalized medicine. The company’s reliance on Palantir Foundry highlights the growing trend of specialized data platforms being integrated with broader analytics infrastructure. The multi-year subscription deals suggest a growing confidence in the value of RWD, but also introduce a longer sales cycle and potential churn risk.
What we're watching
- Conversion Rate
- The sustainability of OneMedNet’s growth hinges on its ability to maintain a high conversion rate from evaluations to paid subscriptions, particularly given the multi-year commitment required.
- Network Scale
- Further expansion of the iRWD network beyond 2,130 sites will be critical to sustaining the upward trajectory of subscription value and attracting larger clients.
- Palantir Dependency
- OneMedNet's reliance on Palantir Foundry introduces a potential point of vulnerability; the company’s performance is intrinsically linked to Palantir’s continued investment and support of the platform.
Related topics